Preliminary NICE ‘no’ for Merck’s Bavencio
The cost regulator has rejecting funding the drug as maintenance treatment of advanced/metastatic urothelial cancer
Read More
Tag: urothelial carcinoma
EMA to consider expanding use of Merck/Pfizer’s Bavencio
The regulator will assess its safety and efficacy as a treatment for bladder cancer
Read More
Merck’s Bavencio hits targets in bladder cancer interim analysis
Last year the drug disappointed in the Phase III JAVELIN Gastric 100 study, but has pulled itself back with new urothelial carcinoma data.
Read More
NICE endorses Keytruda for bladder cancer
MSD’s Keytruda is the first and only immunotherapy to be recommended for NHS use to treat urothelial carcinoma patients, when prior platinum-containing chemotherapy fails.
Read More
Roche’s Tecentriq available via CDF
Roche’s Tecentriq will be available on the NHS in England via the Cancer Drugs Fund for certain patients with metastatic urothelial carcinoma
Read More
BMS’ Opdivo gets ‘breakthrough’ badge for bladder cancer
US regulators have awarded Bristol-Myers Squibb’s immunotherapy Opdivo its sixth breakthrough therapy status, this time for its potential in treating bladder cancer.
Read More
